JAK/STAT Signaling
Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
- A8218 Lapatinib2 CitationTarget: ErbBSummary: EGFR/HER2 inhibitor,potent,selective and reversible
- A8319 Dacomitinib (PF299804, PF299)Target: ErbBSummary: HER inhibitor
- A8375 AZD8931 (Sapitinib)Target: EGFR|ErbBSummary: ErbB inhibitor
- A4092 CUDC-1011 CitationTarget: Histone Deacetylases (HDACs)|EGFR|ErbBSummary: Multitargeted HDAC inhibitor